Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Observational medical record review of newly diagnosed CML-CP participants in China
Chronic Myeloid Leukemia|Philadelphia Chromosome|Chronic Myeloid Leukemia in Chronic Phase
OTHER: Non-Interventional
Number of participants receiving each first-line treatment option, 2 years|Number of participants with complete cytogenetic response, Complete Cytogenetic Response (CCyR): 0% Ph+ cells in metaphase in bone marrow (BM), 2 years|Number of participants with major molecular response (MMR), Major molecular response (MMR) is defined as 3-log reduction in International Scale of BCR-ABL mRNA, 2 years|Number of participants of each initial dose schema, 2 years|Starting dose of each first-line agent, 2 years
Distribution of demographic characteristics, Including age, sex, height, weight, 2 years|Distribution of clinical characteristics, Including health insurance and comorbid conditions, 2 years
Observational medical record review of newly diagnosed CML-CP participants in China